Trial Profile
A phase 2A Proof-of-concept trial of NRX-1074 patients with Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Apimostinel (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- 06 Nov 2015 New trial record
- 04 Nov 2015 According to Allergan media release, company is planning to initiate this trial in first half of 2016